Published in AIDS on November 05, 2004
Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One (2009) 4.52
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in Sub-Saharan Africa. J Acquir Immune Defic Syndr (2009) 2.99
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med (2013) 2.49
Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. J Acquir Immune Defic Syndr (2009) 2.15
Correlates of late HIV diagnosis: implications for testing policy. Int J STD AIDS (2007) 1.78
The problem of late ART initiation in Sub-Saharan Africa: a transient aspect of scale-up or a long-term phenomenon? J Health Care Poor Underserved (2013) 1.75
Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection. Blood (2012) 1.69
Alcohol and HIV disease progression: weighing the evidence. Curr HIV/AIDS Rep (2010) 1.64
Late presenters to HIV care and treatment, identification of associated risk factors in HIV-1 infected Indian population. BMC Public Health (2010) 1.63
Cross-sectional analysis of late HAART initiation in Latin America and the Caribbean: late testers and late presenters. PLoS One (2011) 1.53
Association of age with mortality and virological and immunological response to antiretroviral therapy in rural South African adults. PLoS One (2011) 1.43
The Direct Medical Costs of Late Presentation (<350/mm) of HIV Infection over a 15-Year Period. AIDS Res Treat (2011) 1.41
Combining qualitative and quantitative evidence to determine factors leading to late presentation for antiretroviral therapy in Malawi. PLoS One (2011) 1.38
Risk factors for late-stage HIV disease presentation at initial HIV diagnosis in Durban, South Africa. PLoS One (2013) 1.28
Late entry to HIV care limits the impact of anti-retroviral therapy in The Netherlands. PLoS One (2008) 1.27
Advanced disease at enrollment in HIV care in four sub-Saharan African countries: change from 2006 to 2011 and multilevel predictors in 2011. AIDS (2014) 1.17
Perceived discrimination and physical health among HIV-positive Black and Latino men who have sex with men. AIDS Behav (2013) 1.05
CD4 Cell Counts at HIV Diagnosis among HIV Outpatient Study Participants, 2000-2009. AIDS Res Treat (2011) 1.00
Scaling up antiretroviral treatment services in Karnataka, India: impact on CD4 counts of HIV-infected people. PLoS One (2013) 0.99
Older HIV-infected individuals present late and have a higher mortality: Brighton, UK cohort study. BMC Public Health (2013) 0.97
Trends in missed presentations and late HIV diagnosis in a UK teaching hospital: a retrospective comparative cohort study. BMC Infect Dis (2012) 0.95
Arming of MAIT Cell Cytolytic Antimicrobial Activity Is Induced by IL-7 and Defective in HIV-1 Infection. PLoS Pathog (2015) 0.94
Time since the last HIV test and migration origin in the Paris metropolitan area, France. AIDS Care (2011) 0.93
Evaluation of rapid progressors in HIV infection as an extreme phenotype. J Acquir Immune Defic Syndr (2014) 0.92
Survival outcomes and effect of early vs. deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: a cohort analysis. PLoS One (2011) 0.91
Implementation of a Cloud-Based Electronic Medical Record to Reduce Gaps in the HIV Treatment Continuum in Rural Kenya. PLoS One (2015) 0.91
Time trends and correlates of late presentation for HIV care in Northern Greece during the decade 2000 to 2010. J Int AIDS Soc (2012) 0.87
Health and labor supply in the context of HIV/AIDS: the long-run economic impacts on antiretroviral therapy(). Econ Dev Cult Change (2012) 0.86
Who are California's late HIV testers? An analysis of state AIDS surveillance data, 2000-2006. Public Health Rep (2011) 0.86
Baseline CD4+ T lymphocyte cell counts, hepatitis B and C viruses seropositivity in adults with Human Immunodeficiency Virus infection at a tertiary hospital in Nigeria. Pan Afr Med J (2011) 0.86
Analysis of the immunologic status of a newly diagnosed HIV positive population in China. BMC Infect Dis (2013) 0.86
Severity and outcomes of Pneumocystis pneumonia in patients newly diagnosed with HIV infection: an observational cohort study. Scand J Infect Dis (2009) 0.85
Evolution of HIV treatment guidelines in high- and low-income countries: converging recommendations. Antiviral Res (2013) 0.85
Association of complementary and alternative medicine use with highly active antiretroviral therapy initiation. Altern Ther Health Med (2008) 0.85
Missed opportunities for HIV screening in pharmacies and retail clinics. J Manag Care Spec Pharm (2014) 0.85
Alcohol consumption as a barrier to prior HIV testing in a population-based study in rural Uganda. AIDS Behav (2013) 0.85
Pulmonary toxoplasmosis in human immunodeficiency virus-infected patients in the era of antiretroviral therapy. Lung India (2016) 0.85
Social Network Characteristics Moderate the Association Between Stigmatizing Attributions About HIV and Non-adherence Among Black Americans Living with HIV: a Longitudinal Assessment. Ann Behav Med (2015) 0.84
Stage of HIV presentation at initial clinic visit following a community-based HIV testing campaign in rural Kenya. BMC Public Health (2015) 0.84
Estimation of HIV-testing rates to maximize early diagnosis-derived benefits at the individual and population level. PLoS One (2013) 0.83
Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease. BMC Infect Dis (2011) 0.83
Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010. J Infect Dis (2016) 0.82
Expanded HIV testing coverage is associated with decreases in late HIV diagnoses. AIDS (2015) 0.81
Reduced Central Memory CD4+ T Cells and Increased T-Cell Activation Characterise Treatment-Naive Patients Newly Diagnosed at Late Stage of HIV Infection. AIDS Res Treat (2011) 0.81
Predictors of Late HIV Diagnosis among Adult People Living with HIV/AIDS Who Undertake an Initial CD4 T Cell Evaluation, Northern Ethiopia: A Case-Control Study. PLoS One (2015) 0.80
Temporal Trends in Age at HIV Diagnosis in Cohorts in the United States, the Caribbean, and Central and South America. AIDS Behav (2015) 0.79
Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care. J Int AIDS Soc (2015) 0.79
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo). Antimicrob Agents Chemother (2012) 0.78
Epidemiological and mortality analysis of older adults with HIV in eastern China. Clin Interv Aging (2013) 0.78
The prognosis of late presenters in the era of highly active antiretroviral therapy in serbia. Open Virol J (2009) 0.78
Temporal trends of time to antiretroviral treatment initiation, interruption and modification: examination of patients diagnosed with advanced HIV in Australia. J Int AIDS Soc (2015) 0.78
High prevalence and excess mortality of late presenters among HIV-1, HIV-2 and HIV-1/2 dually infected patients in Guinea-Bissau - a cohort study from West Africa. Pan Afr Med J (2016) 0.77
The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: results from the Italian MASTER Cohort. BMC Public Health (2016) 0.77
Social support and mental health among adults prior to HIV counseling and testing in Durban, South Africa. AIDS Care (2015) 0.77
Evaluation of Baseline CD4+ T Cell Counts and ART Requirement in Newly Diagnosed HIV Seropositive Individuals in a Tertiary Care Hospital of Northern India. J Clin Diagn Res (2016) 0.75
Unmatched Case-Control Study on Late Presentation of HIV Infection in Santiago, Cape Verde (2004-2011). Int J Environ Res Public Health (2016) 0.75
Neighborhood Social Capital in Relation to Late HIV Diagnosis, Linkage to HIV Care, and HIV Care Engagement. AIDS Behav (2016) 0.75
Evidence of Local HIV Transmission in the African Community of King County, Washington. J Immigr Minor Health (2016) 0.75
Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial. Pathog Immun (2017) 0.75
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med (2006) 9.21
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (2008) 8.73
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis (2008) 6.73
Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques (2004) 6.42
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS (2003) 5.61
Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis (2005) 5.20
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med (2005) 4.83
HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ (2009) 4.19
HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med (2012) 4.08
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet (2004) 3.59
Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis (2004) 3.40
The role of HIV in serious diseases other than AIDS. AIDS (2008) 3.39
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis (2008) 3.35
Projected life expectancy of people with HIV according to timing of diagnosis. AIDS (2012) 3.09
Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy? AIDS (2005) 2.96
A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis (2002) 2.87
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS (2010) 2.85
Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet (2004) 2.54
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS (2005) 2.45
Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS (2005) 2.38
Response to combination antiretroviral therapy: variation by age. AIDS (2008) 2.28
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS (2008) 2.27
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med (2012) 2.24
Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis (2009) 2.20
Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J (2006) 2.16
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol (2010) 2.06
The distribution of mitochondrial activity in relation to optic nerve structure. Arch Ophthalmol (2002) 2.06
Newly diagnosed HIV infections: review in UK and Ireland. BMJ (2005) 2.00
Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther (2008) 1.83
Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis (2005) 1.80
Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol (2002) 1.79
Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine? AIDS (2003) 1.78
Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis (2012) 1.76
Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS (2002) 1.74
Lung remodeling in pulmonary tuberculosis. J Infect Dis (2005) 1.71
Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS (2006) 1.71
Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis (2004) 1.70
Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med (2006) 1.69
An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS (2013) 1.64
Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS (2002) 1.63
Utility of the antigen-specific interferon-gamma assay for the management of tuberculosis. Curr Opin Pulm Med (2005) 1.60
When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS (2003) 1.60
Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS (2010) 1.57
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr (2012) 1.53
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS (2005) 1.52
Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS (2006) 1.52
Purified protein derivative-activated type 1 cytokine-producing CD4+ T lymphocytes in the lung: a characteristic feature of active pulmonary and nonpulmonary tuberculosis. J Infect Dis (2002) 1.51
Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS (2007) 1.51
Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr (2003) 1.44
Decline in esophageal candidiasis and use of antimycotics in European patients with HIV. Am J Gastroenterol (2005) 1.42
Symptoms are highly prevalent among HIV outpatients and associated with poor adherence and unprotected sexual intercourse. Sex Transm Infect (2010) 1.40
The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. Cancer (2004) 1.39
Virological rebound after suppression on highly active antiretroviral therapy. AIDS (2003) 1.34
Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis (2010) 1.33
Effect of specific ART drugs on lipid changes and the need for lipid management in children with HIV. J Acquir Immune Defic Syndr (2011) 1.31
Splicing of the mycobacteriophage Bethlehem DnaB intein: identification of a new mechanistic class of inteins that contain an obligate block F nucleophile. J Biol Chem (2009) 1.31
Novel beta-barrel fold in the nuclear magnetic resonance structure of the replicase nonstructural protein 1 from the severe acute respiratory syndrome coronavirus. J Virol (2007) 1.30
Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe. J Acquir Immune Defic Syndr (2006) 1.27
Proteomics analysis unravels the functional repertoire of coronavirus nonstructural protein 3. J Virol (2008) 1.27
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis (2003) 1.25
Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial. J Infect Dis (2012) 1.25
Molecular recognition of oligosaccharide epitopes by a monoclonal Fab specific for Shigella flexneri Y lipopolysaccharide: X-ray structures and thermodynamics. Biochemistry (2002) 1.23
Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2009) 1.23
Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM. AIDS (2015) 1.23
Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. J Acquir Immune Defic Syndr (2002) 1.22
Should HIV therapy be started at a CD4 cell count above 350 cells/microl in asymptomatic HIV-1-infected patients? Curr Opin Infect Dis (2009) 1.21
Does ART prevent HIV transmission among MSM? AIDS (2012) 1.20
Physical and psychological symptoms and risk of virologic rebound among patients with virologic suppression on antiretroviral therapy. J Acquir Immune Defic Syndr (2010) 1.20